Welcome to our new website! To provide a stable and secure experience we are turning on services and departments gradually. Some pages will be unavailable or the content incorrect. This site is currently best viewed on desktop. Please bear with us and continue to check back regularly. If you require immediate assistance please call us on 020 8614 7800 or email info@ion.ac.uk.
Welcome to our new website! To provide a stable and secure experience we are turning on services and departments gradually. Some pages will be unavailable or the content incorrect. This site is currently best viewed on desktop. Please bear with us and continue to check back regularly. If you require immediate assistance please call us on 020 8614 7800 or email info@ion.ac.uk.
New research suggests that melatonin may be connected to the severity of COVID-19, in regards to the development of pneumonia.
A study published this month found that by increasing melatonin with the use of a melatonin receptor agonist, damaging effects of ventilator-induced lung injury could be prevented in rodent models.1
Another study found that melatonin exhibits a therapeutic potential in its ability to modulate the immune system.2 Researchers infected rodents with a highly lethal and infectious influenza virus. They found that co-treatment of these infected rodents with melatonin and an antiviral drug significantly increased their survival rates compared to mice treated only with antivirals alone.
This could suggest that if a patient, regardless of age, has adequate melatonin, the infectiousness of COVID-19 will be greatly reduced, and the chances of developing acute long injury and acute respiratory distress syndrome significantly diminished.
For most people, peak melatonin production is between the hours of 2am-3am, therefore it’s vital to get a good night’s sleep. Here are some useful tips for practising good sleep hygiene:
References